• LinkedIn Social Icon
  • Twitter Social Icon

© 2016-2017 by Virtuvax BV, The Netherlands

Please reload

Recent Posts

Virtuvax for collaboration on your innovation in vaccine development or your biosimilar

May 12, 2017

1/2
Please reload

Featured Posts

Phase I clinical trial data of Mucosis intranasal vaccine against respiratory syncytial virus (RSV) show persistent antibody responses in humans.

February 13, 2019

Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be safe and immunogenic and was shown to induce long-lasting anti-RSV antibodies in healthy adults despite high pre-existing antibody levels. The study was designed as a phase I, randomised, double-blind, placebo-controlled trial in 48 healthy volunteers aged 18-49 year and was executed by Imperial College London. Results were published in the high rated journal AJRCCM. 

The vaccine was developed by Mucosis (NL) and incorporates an RSV-F protein with mutations to maintain a pre-fusion conformation while linkage to the immunostimulatory bacterium-like particle (BLP) provides TLR2-dependent adjuvation. Due to an immediate lack of funding, Mucosis filed for bankruptcy in 2017. Since then, all of the intellectual property, cell lines and materials of Mucosis are being made available by Virtuvax B.V., on behalf of the trustee Mr. Holtz, Bout Advocaten, Groningen, the Netherlands. 

Please reload

Follow Us
Search By Tags